What I found, The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy
@applepedro @richtrinhdiana @LittleHashbrown we are waiting on the NDA submission and FDA approval based on the phase 3 trials first half of 2020.. there is a Feb bio conference where the ontx team are presenting, and I believe we are waiting on the Han X Chinese approval for the drug (they are bought in on pre-approval) there is also trials in Brazil similar to China and 14 other countries involved with Rigb ..so far so good for the drug.. as for the company, they just had 3 offerings(some public some direct) and they have money till 2021..June they need Nasdaq compliance, but I'm sure we will be over $1 by then..as long as the drug works
View original message
  • 1